Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 86.

Symington, J W; Wang, C; Twentyman, J; Owusu-Boaitey, N; Schwendener, R; Núñez, G; Schilling, J D; Mysorekar, I U (2015). ATG16L1 deficiency in macrophages drives clearance of uropathogenic E. coli in an IL-1β-dependent manner. Mucosal immunology, 8:1388-1399.

Lee, Y S; Li, P; Huh, J Y; Hwang, I J; Lu, M; Kim, J I; Ham, M; Talukdar, S; Chen, A; Lu, W J; Bandyopadhyay, G K; Schwendener, R; Olefsky, J; Kim, J B (2011). Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes, 60(10):2474-2483.

Rizzo, A; Monteleone, I; Fina, D; Stolfi, C; Caruso, R; Fantini, M C; Franzè, E; Schwendener, R; Pallone, F; Monteleone, G (2011). Inhibition of colitis by IL-25 associates with induction of alternatively activated macrophages. Inflammatory Bowel Diseases, 18(3):449-459.

Haynes, N M; Hawkins, E D; Li, M; McLaughlin, N M; Hämmerling, G J; Schwendener, R; Winoto, A; Wensky, A; Yagita, H; Takeda, K; Kershaw, M H; Darcy, P K; Smyth, M J (2010). CD11c(+) dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. Journal of Immunology, 185(1):532-541.

Hofer, U; Schlaepfer, E; Baenziger, S; Nischang, M; Regenass, S; Schwendener, R; Kempf, W; Nadal, D; Speck, R F (2010). Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathogens, 6(4):e1000867.

Ibrahim-Granet, O; Jouvion, G; Hohl, T M; Droin-Bergère, S; Philippart, F; Kim, O Y; Adib-Conquy, M; Schwendener, R; Cavaillon, J-M; Brock, M (2010). In vivo bioluminescence imaging and histopathopathologic analysis reveal distinct roles for resident and recruited immune effector cells in defense against invasive aspergillosis. BMC Microbiology, 10:105.

Andrés, G; Leali, D; Mitola, S; Coltrini, D; Camozzi, M; Corsini, M; Belleri, M; Hirsch, E; Schwendener, R; Christofori, G; Alcamí, A; Presta, M (2009). A pro-inflammatory signature mediates FGF2-induced angiogenesis. Journal of Cellular and Molecular Medicine, 13(8b):2083-2108.

Torroella-Kouri, M; Silvera, R; Rodriguez, D; Caso, R; Shatry, A; Opiela, S; Ilkovitch, D; Schwendener, R; Iragavarapu-Charyulu, V; Cardentey, Y; Strbo, N; Lopez, D M (2009). Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Research, 69(11):4800-4809.

Gunsten, S; Mikols, C L; Grayson, M H; Schwendener, R; Agapov, E; Tidwell, R M; Cannon, C L; Brody, S L; Walter, M J (2009). IL-12 p80-dependent macrophage recruitment primes the host for increased survival following a lethal respiratory viral infection. Immunology, 126(4):500-513.

Schott, H; Hamprecht, K; Schott, S; Schott, T C; Schwendener, R (2009). Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue. Bioorganic & Medicinal Chemistry, 17(1):303-310.

Kataru, R P; Jung, K; Jang, C; Yang, H; Schwendener, R; Baik, J E; Han, S H; Alitalo, K; Koh, G Y (2009). Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood, 113(22):5650-5659.

Zumsteg, A; Baeriswyl, V; Imaizumi, N; Schwendener, R; Rüegg, C; Christofori, G (2009). Myeloid cells contribute to tumor lymphangiogenesis. PLoS ONE, 4(9):e7067.

Kim, K E; Koh, Y J; Jeon, B H; Jang, C; Han, J; Kataru, R P; Schwendener, R; Kim, J M; Koh, G Y (2009). Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm. American Journal of Pathology, 175(4):1733-1745.

Schott, H; Schott, S; Schwendener, R (2009). Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding. Bioorganic & Medicinal Chemistry, 17(19):6824-6831.

Sayi, A; Kohler, E; Hitzler, I; Arnold, I; Schwendener, R; Rehrauer, H; Müller, A (2009). The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. Journal of Immunology, 182(11):7085-7101.

Kim, D D; Miwa, T; Kimura, Y; Schwendener, R; van Lookeren Campagne, M; Song, W C (2008). Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg. Blood, 112(4):1109-1119.

Hippert, C; Dubois, G; Morin, C; Disson, O; Ibanes, S; Jacquet, C; Schwendener, R; Antignac, C; Kremer, E J; Kalatzis, V (2008). Gene transfer may be preventive but not curative for a lysosomal transport disorder. Molecular Therapy, 16(8):1372-81.

Bijnsdorp, I V; Schwendener, R; Schott, H; Schott, S; Fichtner, I; Honeywell, R J; Losekoot, N; Laan, A C; Peters, G J (2008). In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine. Nucleic Acids Symposium Series (2004), (52):651.

Shen, W; Liu, Y; Zhu, J; Schwendener, R; Huard, J (2008). Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury. Journal of Cellular Physiology, 214(2):405-412.

Ren, W; Markel, D C; Schwendener, R; Ding, Y; Wu, B; Wooley, P H (2008). Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. Journal of Biomedical Materials Research Part A, 85(4):1043-1051.

Wang, J; Barke, R A; Charboneau, R; Schwendener, R; Roy, S (2008). Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappaB signaling. Journal of Immunology, 180(5):3594-3600.

Hauk, T G; Müller, A; Lee-Thorp, J; Schwendener, R; Fischer, D (2008). Neuroprotective and axon growth promoting effects of intraocular inflammation do not depend on oncomodulin or the presence of large numbers of activated macrophages. Experimental Neurology, 209(2):469-482.

Kim, E Y; Battaile, J T; Patel, A C; You, Y; Agapov, E; Grayson, M H; Benoit, L A; Byers, D E; Alevy, Y; Tucker, J; Swanson, S; Tidwell, R; Tyner, J W; Morton, J D; Castro, M; Polineni, D; Patterson, G A; Schwendener, R; Allard, J D; Peltz, G; Holtzman, M J (2008). Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nature Medicine, 14(6):633-640.

Jeon, B H; Jang, C; Han, J; Kataru, R P; Piao, L; Jung, K; Cha, H J; Schwendener, R; Jang, K Y; Kim, K S; Alitalo, K; Koh, G Y (2008). Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Research, 68(4):1100-9.

Zehnder-Fjällman, A H M; Marty, C; Halin, C; Hohn, A; Schibli, R; Ballmer-Hofer, K; Schwendener, R (2007). Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis. Oncology Reports, 18(4):933-941.

Cho, C H; Koh, Y J; Han, J; Sung, H K; Jong Lee, H; Morisada, T; Schwendener, R; Brekken, R A; Kang, G; Oike, Y; Choi, T S; Suda, T; Yoo, O J; Koh, G Y (2007). Angiogenic role of LYVE-1-positive macrophages in adipose tissue. Circulation Research, 100(4):e47-e57.

Schwendener, R (2007). Delivery Systems for Peptides/Oligonucleotides and Lipophilic Nucleoside Analogs. In: Gad, S C. Handbook of Pharmaceutical Biotechnology. Hoboken, New Jersey, USA: John Wiley & Sons, 1149-1172.

Bijnsdorp, I V; Schwendener, R; Schott, H; Fichtner, I; Smid, K; Schott, S; Laan, A C; Peters, G J (2007). In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine. Nucleosides, Nucleotides and Nucleic Acids, 26(10-12):1619-1624.

Schwendener, R (2007). Liposomes in biology and medicine. In: Chan, W C W. Bio-Applications of Nanoparticles. New York: Springer, 117-128.

Zeisberger, S M; Odermatt, B; Marty, C; Zehnder-Fjällman, A H M; Ballmer-Hofer, K; Schwendener, R (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer, 95(3):272-281.

Marty, C; Langer-Machova, Z; Sigrist, S; Schott, H; Schwendener, R; Ballmer-Hofer, K (2006). Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy. Cancer Letters, 235(2):298-308.

Lasbury, M E; Durant, P J; Ray, C A; Tschang, D; Schwendener, R; Lee, C H (2006). Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia. Journal of Immunology, 176(11):6443-6453.

Beck-Schimmer, B; Schwendener, R; Pasch, T; Reyes, L; Booy, C; Schimmer, R C (2005). Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury. Respiratory Research, 6:61.

Tyner, J W; Uchida, O; Kajiwara, N; Kim, E Y; Patel, A C; O'Sullivan, M P; Walter, M J; Schwendener, R; Cook, D N; Danoff, T M; Holtzman, M J (2005). CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature Medicine, 11(11):1180-1187.

Marty, C; Schwendener, R (2005). Cytotoxic tumor targeting with scFv antibody-modified liposomes. In: Ludewig, B; Hoffmann, M W. Adoptive Immunotherapy: Methods and Protocols. Springer: Humana Press, 389-401.

Probst, H C; Tschannen, K; Odermatt, B; Schwendener, R; Zinkernagel, R M; van den Broek, Maries (2005). Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clinical and Experimental Immunology, 141(3):398-404.

Schwendener, R; Schott, H (2005). Lipophilic arabinofuranosyl cytosine derivatives in liposomes. Methods in Enzymology, 391:58-70.

Robinson, J A; Shankaramma, S C; Jetter, P; Kienzl, U; Schwendener, R; Vrijbloed, J W; Obrecht, D (2005). Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I. Bioorganic & Medicinal Chemistry, 13(6):2055-2064.

Beck-Schimmer, B; Rosenberger, D S; Neff, S B; Jamnicki, M; Suter, D; Fuhrer, T; Schwendener, R; Booy, C; Reyes, L; Pasch, T; Schimmer, R C (2005). Pulmonary aspiration: new therapeutic approaches in the experimental model. Anesthesiology, 103(3):556-566.

Ludwig, P S; Schwendener, R; Schott, H (2005). Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs. European Journal of Medicinal Chemistry, 40(5):494-504.

Rubio Demirovic, A; Marty, C; Console, S; Zeisberger, S M; Ruch, C; Jaussi, R; Schwendener, R; Ballmer-Hofer, K (2005). Targeting human cancer cells with VEGF receptor-2-directed liposomes. Oncology Reports, 13(2):319-324.

Engler, O B; Schwendener, R; Dai, W J; Wölk, B; Pichler, W; Moradpour, D; Brunner, T; Cerny, A (2004). A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins. Vaccine, 23(1):58-68.

Marty, C; Meylan, C; Schott, H; Ballmer-Hofer, K; Schwendener, R (2004). Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cellular and Molecular Life Sciences, 61(14):1785-1794.

Storni, T; Ruedl, C; Schwarz, K; Schwendener, R; Renner, W A; Bachmann, M F (2004). Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. Journal of Immunology, 172(3):1777-1785.

Console, S; Marty, C; García-Echeverría, C; Schwendener, R; Ballmer-Hofer, K (2003). Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. Journal of Biological Chemistry, 278(37):35109-35114.

Madjdpour, C; Jewell, U R; Kneller, S; Ziegler, U; Schwendener, R; Booy, C; Kläusli, L; Pasch, T; Schimmer, R C; Beck-Schimmer, B (2003). Decreased alveolar oxygen induces lung inflammation. American Journal of Physiology: Lung Cellular and Molecular Physiology, 284(2):L360-L367.

Aichele, P; Zinke, J; Grode, L; Schwendener, R; Kaufmann, S H E; Seiler, P (2003). Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. Journal of Immunology, 171(3):1148-1155.

Marty, C; Odermatt, B; Schott, H; Neri, D; Ballmer-Hofer, K; Klemenz, R; Schwendener, R (2002). Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. British Journal of Cancer, 87(1):106-112.

Schwendener, R; Friedl, K; Depenbrock, H; Schott, H; Hanauske, A R (2001). In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells. Investigational New Drugs, 19(3):203-210.

Seiler, P; Schwendener, R; Bandermann, S; Brinkmann, V; Grode, L; Kaufmann, S H E; Aichele, P (2001). Limited mycobacterial infection of the liver as a consequence of its microanatomical structure causing restriction of mycobacterial growth to professional phagocytes. Infection and Immunity, 69(12):7922-7926.

Marty, C; Scheidegger, P; Ballmer-Hofer, K; Klemenz, R; Schwendener, R (2001). Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris. Protein Expression and Purification, 21(1):156-164.

Roscic-Mrkic, B; Schwendener, R; Odermatt, B; Zuniga, A; Pavlovic, J; Billeter, M A; Cattaneo, R (2001). Roles of macrophages in measles virus infection of genetically modified mice. Journal of Virology, 75(7):3343-3351.

Cattaneo-Pangrazzi, R M; Schott, H; Wunderli-Allenspach, H; Rothen-Rutishauser, B; Guenthert, M; Schwendener, R (2000). Cell-cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 human prostate cancer cells. Journal of Cancer Research and Clinical Oncology, 126(5):247-256.

Horber, D H; Cattaneo-Pangrazzi, R M; von Ballmoos, P; Schott, H; Ludwig, P S; Eriksson, S; Fichtner, I; Schwendener, R (2000). Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne. Journal of Cancer Research and Clinical Oncology, 126(6):311-319.

Ludewig, B; Barchiesi, F; Pericin, M; Zinkernagel, R M; Hengartner, H; Schwendener, R (2000). In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity. Vaccine, 19(1):23-32.

Cattaneo-Pangrazzi, R M; Schott, H; Wunderli-Allenspach, H; Derighetti, M; Schwendener, R (2000). Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells. Biochemical Pharmacology, 60(12):1887-96.

Cattaneo-Pangrazzi, R M; Schott, H; Schwendener, R (2000). The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate, 45(1):8-18.

Koller-Lucae, S K; Schott, H; Schwendener, R (1999). Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells. British Journal of Cancer, 80(10):1542-9.

Koller-Lucae, S K; Suter, M J; Rentsch, K M; Schott, H; Schwendener, R (1999). Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice. Drug Metabolism and Disposition, 27(3):342-350.

Ludewig, B; Oehen, S; Barchiesi, F; Schwendener, R; Hengartner, H; Zinkernagel, R M (1999). Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. Journal of Immunology, 163(4):1839-1844.

Schwendener, R; Peghini, P A; Ludwing, P S; Schott, H (1999). Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT. Nucleosides and Nucleotides, 18(4-5):949-950.

Peghini, P A; Zahner, R; Kuster, H; Schott, H; Schwendener, R (1998). In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC. Antiviral Chemistry & Chemotherapy, 9(2):117-126.

Rentsch, K M; Schwendener, R; Pestalozzi, B C; Sauter, C; Wunderli-Allenspach, H; Hänseler, E (1998). Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. European Journal of Clinical Pharmacology, 54(1):83-89.

van Borssum Waalkes, M; Goris, H; Dontje, B H; Schwendener, R; Scherphof, G; Nijhof, W (1998). Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice. Anti-Cancer Drug Design, 13(4):291-305.

Rentsch, K M; Horber, D H; Schwendener, R; Wunderli-Allenspach, H; Hänseler, E (1997). Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. British Journal of Cancer, 75(7):986-992.

Seiler, P; Aichele, P; Odermatt, B; Hengartner, H; Zinkernagel, R M; Schwendener, R (1997). Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection. European Journal of Immunology, 27(10):2626-2633.

Koller-Lucae, S K; Schott, H; Schwendener, R (1997). Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. Journal of Pharmacology and Experimental Therapeutics, 282(3):1572-1580.

Frankenberger, M; Hofmann, B; Emmerich, B; Nerl, C; Schwendener, R; Ziegler-Heitbrock, H W (1997). Liposomal 1,25 (OH)2 vitamin D3 compounds block proliferation and induce differentiation in myelomonocytic leukaemia cells. British Journal of Haematology, 98(1):186-194.

Rentsch, K M; Schwendener, R; Schott, H; Hänseler, E (1997). Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice. Journal of Pharmacy and Pharmacology, 49(11):1076-1081.

Rentsch, K M; Schwendener, R; Hänseler, E (1996). Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Applications, 679(1-2):185-192.

Schwendener, R; Schott, H (1996). Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. Journal of Cancer Research and Clinical Oncology, 122(12):723-726.

Schwendener, R; Horber, D H; Odermatt, B; Schott, H (1996). Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine. Journal of Cancer Research and Clinical Oncology, 122(2):102-108.

Schott, H; Schwendener, R (1996). Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates. Anti-Cancer Drug Design, 11(6):451-62.

Horber, D H; von Ballmoos, P; Schott, H; Schwendener, R (1995). Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine. British Journal of Cancer, 72(5):1067-1073.

Horber, D H; Schott, H; Schwendener, R (1995). Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemotherapy and Pharmacology, 36(6):483-492.

Horber, D H; Schott, H; Schwendener, R (1995). Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine. British Journal of Cancer, 71(5):957-962.

Horber, D H; Ottiger, C; Schott, H; Schwendener, R (1995). Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. Journal of Pharmacy and Pharmacology, 47(4):282-288.

Pestalozzi, B C; Vass, A; Adam, H; Horber, D H; Schwendener, R; Sauter, C (1995). Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. European Journal of Cancer, 31A(6):1024.

Rentsch, K M; Schwendener, R; Schott, H; Hänseler, E (1995). Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes. Journal of Chromatography. B, Biomedical Applications, 673(2):259-266.

Schwendener, R; Gowland, P; Horber, D H; Zahner, R; Schertler, A; Schott, H (1994). New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens. Antiviral Research, 24(1):79-93.

Condrau, M A; Schwendener, R; Niederer, P; Anliker, M (1994). Time-resolved flow cytometry for the measurement of lanthanide chelate fluorescence: I. Concept and theoretical evaluation. Cytometry Part A, 16(3):187-194.

Condrau, M A; Schwendener, R; Zimmermann, M; Muser, M H; Graf, U; Niederer, P; Anliker, M (1994). Time-resolved flow cytometry for the measurement of lanthanide chelate fluorescence: II. Instrument design and experimental results. Cytometry Part A, 16(3):195-205.

Pestalozzi, B; Schwendener, R; Sauter, C (1992). Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Annals of Oncology, 3(6):445-449.

Schwendener, R; Schott, H (1992). Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine. International Journal of Cancer, 51(3):466-469.

Schwendener, R; Fiebig, H H; Berger, M R; Berger, D P (1991). Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Cancer Chemotherapy and Pharmacology, 27(6):429-439.

Schwendener, R; Wüthrich, R; Duewell, S; Wehrli, E; von Schulthess, G K (1990). A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Investigative Radiology, 25(8):922-932.

This list was generated on Fri Oct 20 19:08:03 2017 CEST.